Corrigendum

Association of CTLA-4 gene variants with response to therapy and long-term survival in metastatic melanoma patients treated with ipilimumab: An Italian melanoma intergroup study [Front Immunol, 8, (2017), (386)] doi: 10.3389/fimmu.2017.00386

on behalf of the Italian Melanoma Intergroup (IMI)

Research output: Contribution to journalComment/debate

1 Citation (Scopus)

Abstract

A corrigendum on Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study by Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, et al. Front Immunol (2017) 8:386. doi: 10.3389/fimmu.2017.00386. In the original article, affiliation number 9 was wrong. The correct affiliation 9 is "Istituto Dermopatico dell'Immacolata IDI-IRCCS, Rome, Italy". This error does not change the scientific conclusions of the article in any way. The original article has been updated. Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Original languageEnglish
Article number403
JournalFrontiers in Immunology
Volume9
Issue numberMAR
DOIs
Publication statusPublished - Mar 2 2018

Fingerprint

Conflict of Interest
Melanoma
Survival
Italy
Genes
Therapeutics
Research
ipilimumab
corrigendum

Keywords

  • Best overall response
  • CTLA-4 variants
  • Ipilimumab
  • Melanoma
  • Overall survival
  • Predictive/prognostic factor

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

@article{cf7c9f05529c4065b953334ad8a6823a,
title = "Corrigendum: Association of CTLA-4 gene variants with response to therapy and long-term survival in metastatic melanoma patients treated with ipilimumab: An Italian melanoma intergroup study [Front Immunol, 8, (2017), (386)] doi: 10.3389/fimmu.2017.00386",
abstract = "A corrigendum on Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study by Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, et al. Front Immunol (2017) 8:386. doi: 10.3389/fimmu.2017.00386. In the original article, affiliation number 9 was wrong. The correct affiliation 9 is {"}Istituto Dermopatico dell'Immacolata IDI-IRCCS, Rome, Italy{"}. This error does not change the scientific conclusions of the article in any way. The original article has been updated. Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.",
keywords = "Best overall response, CTLA-4 variants, Ipilimumab, Melanoma, Overall survival, Predictive/prognostic factor",
author = "{on behalf of the Italian Melanoma Intergroup (IMI)} and Paola Queirolo and Beatrice Dozin and Anna Morabito and Barbara Banelli and Patrizia Piccioli and Cristiana Fava and Claudio Leo and Roberta Carosio and Stefania Laurent and Vincenzo Fontana and Ferrucci, {Pier Francesco} and Chiara Martinoli and Emilia Cocorocchio and Angelo Battaglia and Ascierto, {Paolo A.} and Mariaelena Capone and Ester Simeone and {De Galitiis}, Federica and Elena Pagani and Cappellini, {Gian Carlo Antonini} and Paolo Marchetti and Michele Guida and Stefania Tommasi and Mario Mandal{\`a} and Barbara Merelli and Pietro Quaglino and Paolo Fava and Massimo Guidoboni and Massimo Romani and Francesco Spagnolo and Pistillo, {Maria Pia}",
year = "2018",
month = "3",
day = "2",
doi = "10.3389/fimmu.2018.00403",
language = "English",
volume = "9",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S.A.",
number = "MAR",

}

TY - JOUR

T1 - Corrigendum

T2 - Association of CTLA-4 gene variants with response to therapy and long-term survival in metastatic melanoma patients treated with ipilimumab: An Italian melanoma intergroup study [Front Immunol, 8, (2017), (386)] doi: 10.3389/fimmu.2017.00386

AU - on behalf of the Italian Melanoma Intergroup (IMI)

AU - Queirolo, Paola

AU - Dozin, Beatrice

AU - Morabito, Anna

AU - Banelli, Barbara

AU - Piccioli, Patrizia

AU - Fava, Cristiana

AU - Leo, Claudio

AU - Carosio, Roberta

AU - Laurent, Stefania

AU - Fontana, Vincenzo

AU - Ferrucci, Pier Francesco

AU - Martinoli, Chiara

AU - Cocorocchio, Emilia

AU - Battaglia, Angelo

AU - Ascierto, Paolo A.

AU - Capone, Mariaelena

AU - Simeone, Ester

AU - De Galitiis, Federica

AU - Pagani, Elena

AU - Cappellini, Gian Carlo Antonini

AU - Marchetti, Paolo

AU - Guida, Michele

AU - Tommasi, Stefania

AU - Mandalà, Mario

AU - Merelli, Barbara

AU - Quaglino, Pietro

AU - Fava, Paolo

AU - Guidoboni, Massimo

AU - Romani, Massimo

AU - Spagnolo, Francesco

AU - Pistillo, Maria Pia

PY - 2018/3/2

Y1 - 2018/3/2

N2 - A corrigendum on Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study by Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, et al. Front Immunol (2017) 8:386. doi: 10.3389/fimmu.2017.00386. In the original article, affiliation number 9 was wrong. The correct affiliation 9 is "Istituto Dermopatico dell'Immacolata IDI-IRCCS, Rome, Italy". This error does not change the scientific conclusions of the article in any way. The original article has been updated. Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

AB - A corrigendum on Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study by Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, et al. Front Immunol (2017) 8:386. doi: 10.3389/fimmu.2017.00386. In the original article, affiliation number 9 was wrong. The correct affiliation 9 is "Istituto Dermopatico dell'Immacolata IDI-IRCCS, Rome, Italy". This error does not change the scientific conclusions of the article in any way. The original article has been updated. Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

KW - Best overall response

KW - CTLA-4 variants

KW - Ipilimumab

KW - Melanoma

KW - Overall survival

KW - Predictive/prognostic factor

UR - http://www.scopus.com/inward/record.url?scp=85042698051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042698051&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2018.00403

DO - 10.3389/fimmu.2018.00403

M3 - Comment/debate

VL - 9

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - MAR

M1 - 403

ER -